Inceptive announced a strategic collaboration with Alnylam Pharmaceuticals
The partnership, valued at up to $2 billion, aims to use AI foundation models for oligonucleotide design.
See the latest news and media coverage for Inceptive. We track all announcements, press releases, and industry mentions in real time, all in one place.
AI foundation model developer for drug discovery
inceptive.comLast updated
In short: Inceptive collaborated with Alnylam on a $2 billion RNAi project and raised $100 million to apply AI foundation models to drug discovery.
The partnership, valued at up to $2 billion, aims to use AI foundation models for oligonucleotide design.
Radical Numerics is betting that the future of bio-defense and AI drug discovery lies in understandi...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration...
Reuters: Sources: Microsoft is in discussions to acquire LLM developer Inception; SpaceX also courted Inception, which is looking for a price of over $1B...
Track Inceptive and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Inceptive and other trending companies.